Back to top
more

Sage Therapeutics (SAGE)

(Delayed Data from NSDQ)

$6.05 USD

6.05
1,060,671

-0.03 (-0.49%)

Updated Nov 1, 2024 03:59 PM ET

After-Market: $6.06 +0.01 (0.17%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.10%
2Buy17.80%
3Hold9.50%
4Sell2.70%
5Strong Sell2.70%
S&P50011.20%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

F Value C Growth C Momentum D VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 32% (79 out of 250)

Industry: Medical - Drugs

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Better trading starts here.

Zacks News

Should WisdomTree U.S. SmallCap ETF (EES) Be on Your Investing Radar?

by Zacks Equity Research

Style Box ETF report for EES

The Zacks Analyst Blog Highlights Regeneron Pharmaceuticals, Sage Therapeutics, Biogen Agios Pharmaceuticals Atara Biotherapeutics

by Zacks Equity Research

Regeneron Pharmaceuticals, Sage Therapeutics, Biogen Agios Pharmaceuticals Atara Biotherapeutics are included in this blog.

Sage Therapeutics, Inc. (SAGE) Reports Q4 Loss, Misses Revenue Estimates

by Zacks Equity Research

Sage Therapeutics, Inc. (SAGE) delivered earnings and revenue surprises of 1.85% and 8.27%, respectively, for the quarter ended December 2021. Do the numbers hold clues to what lies ahead for the stock?

Is WisdomTree U.S. SmallCap ETF (EES) a Strong ETF Right Now?

by Zacks Equity Research

Smart Beta ETF report for EES

Biotech Stock Roundup: SAGE, ATRA Down on Study Updates, AGIO Drug Approval & More

by Zacks Equity Research

Updates from SAGE and Atara (ATRA) are among a few key highlights from the biotech sector during the past week.

Sage Therapeutics, Inc. (SAGE) May Report Negative Earnings: Know the Trend Ahead of Next Week's Release

by Zacks Equity Research

Sage Therapeutics, Inc. (SAGE) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Sage Therapeutics (SAGE) Depression Drug Meets Goal, Stock Down

by Zacks Equity Research

Sage Therapeutics (SAGE) and Biogen's (BIIB) depression candidate, zuranolone given along with antidepressants improves depressive symptoms in a phase III study. Questions remain about the durability of the drug.

What Makes Sage Therapeutics, Inc. (SAGE) a New Buy Stock

by Zacks Equity Research

Sage Therapeutics, Inc. (SAGE) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).

Sweta Jaiswal, FRM headshot

Diversify Your Portfolio With a New Psychedelic Drug ETF

by Sweta Jaiswal, FRM

A new thematic ETF providing exposure to the medicinal psychedelic drug industry, PSYK ETF, has just been launched.

Taro Pharmaceutical (TARO) Q3 Earnings and Revenues Miss Estimates

by Zacks Equity Research

Taro (TARO) delivered earnings and revenue surprises of -23.08% and 2.26%, respectively, for the quarter ended December 2021. Do the numbers hold clues to what lies ahead for the stock?

Sage (SAGE), Biogen (BIIB) Report Data on Depression Drug

by Zacks Equity Research

Sage Therapeutics (SAGE) and partner Biogen (BIIB) announce positive data from a cohort of an ongoing phase III study, currently evaluating their investigational major depressive disorder drug zuranolone.

Sage Therapeutics, Inc. (SAGE) Reports Q3 Loss, Lags Revenue Estimates

by Zacks Equity Research

Sage Therapeutics, Inc. (SAGE) delivered earnings and revenue surprises of -20.11% and -28.04%, respectively, for the quarter ended September 2021. Do the numbers hold clues to what lies ahead for the stock?

Should You Buy Sage Therapeutics (SAGE) Ahead of Earnings?

by Zacks Equity Research

Sage Therapeutics (SAGE) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.

Sage Therapeutics, Inc. (SAGE) Expected to Beat Earnings Estimates: Should You Buy?

by Zacks Equity Research

Sage Therapeutics, Inc. (SAGE) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Sage, Biogen Plan to File Zuranolone NDA for MDD in 2022

by Zacks Equity Research

Sage (SAGE) and partner Biogen are looking to get approval for zuranolone as an oral treatment for major depressive disorder. They will start rolling submission of an NDA in early 2022 for the candidate.

Biogen (BIIB) Stock Up This Year So Far on Aduhelm Approval

by Zacks Equity Research

Biogen's (BIIB) new Alzheimer's drug, Aduhelm should bring in huge revenues, if successfully commercialized.

Sage Therapeutics, Inc. (SAGE) Reports Q2 Loss, Lags Revenue Estimates

by Zacks Equity Research

Sage Therapeutics, Inc. (SAGE) delivered earnings and revenue surprises of -8.28% and -19.34%, respectively, for the quarter ended June 2021. Do the numbers hold clues to what lies ahead for the stock?

Sage Therapeutics, Inc. (SAGE) May Report Negative Earnings: Know the Trend Ahead of Next Week's Release

by Zacks Equity Research

Sage Therapeutics, Inc. (SAGE) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Biotech Stock Roundup: SAGE Declines on Data, Regulatory Updates From VRTX, ITOS

by Zacks Equity Research

The biotech sector was in focus last week with regulatory updates from Sage (SAGE) and Vertex (VRTX), among others.

Sage Stock Declines on Late-Stage Depression Study Data

by Zacks Equity Research

Sage is developing zuranolone as a potential treatment for major depression disorder in late-stage studies.

Biogen (BIIB) 2nd Eye Disease Gene Therapy Misses Study Goal

by Zacks Equity Research

Biogen's (BIIB) rare, inherited retinal disease gene therapy candidate, timrepigene emparvovec, fails to meet the primary endpoint in a phase III study.

Is the Options Market Predicting a Spike in Sage Therapeutics (SAGE) Stock?

by Zacks Equity Research

Investors need to pay close attention to Sage Therapeutics (SAGE) stock based on the movements in the options market lately.

Biogen (BIIB) Eye Disease Drug Misses Primary Goal in Study

by Zacks Equity Research

Biogen's (BIIB) rare, inherited retinal disease candidate, cotoretigene toliparvovec fails to meet the primary endpoint in a phase II/III study.

Biogen (BIIB) Decides to Acquire Phase II Stroke Candidate

by Zacks Equity Research

Biogen's (BIIB) decision to acquire TMS-007 is based on positive data from a phase IIa study, which met its primary safety objective with no incidence of symptomatic intracranial hemorrhage (sICH)

Implied Volatility Surging for Sage Therapeutics (SAGE) Stock Options

by Zacks Equity Research

Investors need to pay close attention to Sage Therapeutics (SAGE) stock based on the movements in the options market lately.